Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-017: pembrolizumab + lenvatinib vs standard of care in metastatic colorectal cancer
jRCT2031200453Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised trial in colorectal adenocarcinoma comparing Pembrolizumab + lenvatinib with Standard of care (regorafenib or TAS-102) (2 arms). Primary endpoint: Overall survival. Started May 2021; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on jRCT2031200453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200453.